“Not to underline the obvious, but he is the Chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, where we started (but apparently did not finish) a study testing Leron w Keytruda in a breast cancer xenograft model. The study was undertaken to evaluate synergistic effects of Leronlimab and Keytruda.”

I recall discussing this on the board some months ago. Whatever happened to this study, I mean. What I vaguely recall, is we did not initiate or fund the study, therefore we don’t own the results. We simply provided our drug. Discussion here veered towards what if the results were significant? Would Merck run to the presses, or hold the cards close to their chest? Perhaps the question is its own reply.